Giulia Di Pietro

Giulia Di Pietro

Auto-generated profile, based on publicly available information

Giulia Di Pietro

Department of Chemical Science and Technologies, University of Rome Tor Vergata, Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2013 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
Silvia CapuaniSilvia Capuani
Silvia Capuani
EPEleonora Piccirilli
Eleonora Piccirilli
GPGiulia Di Pietro
Giulia Di Pietro
MCMonica Celi
Monica Celi
Umberto TarantinoUmberto Tarantino
Umberto Tarantino

12 October 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AGAlessandra Guidi
Alessandra Guidi
Greta PetrellaGreta Petrella
Greta Petrella
VFValentina Fustaino
Valentina Fustaino
FSFulvio Saccoccia
Fulvio Saccoccia
SLSara Lentini
Sara Lentini
GRGiovina Ruberti
Giovina Ruberti
Schistosomiasis is one of the most devastating neglected tropical parasitic diseases caused by trematodes of the genus Schistosoma. Praziquantel (PZQ) is today the only drug used in humans and animals for the treatment of schistosomiasis but unfortunately it is poorly effective on larval and juvenile stages of the parasite. Therefore, it is urgent the discovery of new drug targets and compounds. We have recently showed that the anti-anginal drug perhexiline maleate (PHX) is very active on multiple developmental stages of Schistosoma mansoni in vitro. It is well known that PHX impacts the lipid metabolism in mammals, but the final target on schistosomes still remains unknown. The aim of this study was to evaluate the ability of 1H nuclear magnetic resonance (NMR) spectroscopy in revealing metabolic perturbations due to PHX treatment of S. mansoni adult male worms. The effects of PHX were compared with the ones induced by vehicle and gambogic acid, in order to detect different metabolic profiles and specificity of the PHX action. Remarkably a list of metabolites associated to PHX-treatment was identified with enrichment in several connected metabolic pathways including also the Kennedy pathway mediating the glycerophospholipid metabolism. Our study represents the first 1H-NMR metabolomic approach to characterize the response of S. mansoni to drug treatment. The obtained “metabolic fingerprint” associated to PHX treatment could represent a strategy for displaying cellular metabolic changes for any given drug and to compare compounds targeting similar or distinct biochemical pathways. Schistosomiasis is a chronic and debilitating neglected tropical parasitic disease caused by the helminth Schistosoma. The control and treatment of the disease rely almost exclusively on praziquantel (PZQ), poorly effective on some developmental stage of the parasite. Identification of novel targets and drugs is required. The aim of this study was to use a 1H-NMR metabolomic approach to characterize the response of Schistosoma mansoni to perhexiline maleate (PHX), a multi-stage schistosomicidal drug previously investigated by our group. Remarkably we identified a metabolic signature specifically associated to drug-treatment in adult male parasites. This approach could contribute to the identification of novel targets and biochemical pathways implicated in parasite development and survival.